Regeneron to buy 23andMe for $256M in court-supervised sale
Source: SeekingAlpha
2025-05-19 07:32:26 ET
More on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals, Inc. (REGN) BofA Securities 2025 Healthcare Conference (Transcript)
- Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
- Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
- Notable analyst calls this week: Caterpillar, UnitedHealth and Peloton among top picks
- Regeneron wins over $400M jury award as Amgen found liable in antitrust case
Read the full article on Seeking Alpha
For further details see:
Regeneron to buy 23andMe for $256M in court-supervised sale
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-1.59% G/L:
$742.885 Last:
150,713 Volume:
$754.55 Open:
REGN Latest News
March 12, 2026 04:04:00 am
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
